A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats

Masahiro Shinoda, Arno W. Tilles, Naoya Kobayashi, Go Wakabayashi, Atsushi Takayanagi, Toshinori Totsugawa, Hirohisa Harada, Hideaki Obara, Kazuhiro Suganuma, François Berthiaume, Motohide Shimazu, Nobuyoshi Shimizu, Noriaki Tanaka, Masaki Kitajima, Ronald G. Tompkins, Mehmet Toner, Martin L. Yarmush

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods: We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results: Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion: Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF.

Original languageEnglish
Pages (from-to)130-140
Number of pages11
JournalJournal of Surgical Research
Volume137
Issue number1
DOIs
Publication statusPublished - 2007 Jan

Fingerprint

Artificial Liver
Interleukin-1 Receptors
Acute Liver Failure
Liver Failure
Treatment Failure
Galactosamine
Hepatocytes
Equipment and Supplies
Interleukin 1 Receptor Antagonist Protein
Liver
Interleukin-6
Therapeutics
Portal Vein
Liver Transplantation
Perfusion
Tissue Donors
Survival
Enzymes

Keywords

  • bio-artificial liver device
  • fulminant hepatic failure
  • immortalized human hepatocytes
  • interleukin-1 receptor antagonist
  • primary rat hepatocytes

ASJC Scopus subject areas

  • Surgery

Cite this

A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats. / Shinoda, Masahiro; Tilles, Arno W.; Kobayashi, Naoya; Wakabayashi, Go; Takayanagi, Atsushi; Totsugawa, Toshinori; Harada, Hirohisa; Obara, Hideaki; Suganuma, Kazuhiro; Berthiaume, François; Shimazu, Motohide; Shimizu, Nobuyoshi; Tanaka, Noriaki; Kitajima, Masaki; Tompkins, Ronald G.; Toner, Mehmet; Yarmush, Martin L.

In: Journal of Surgical Research, Vol. 137, No. 1, 01.2007, p. 130-140.

Research output: Contribution to journalArticle

Shinoda, M, Tilles, AW, Kobayashi, N, Wakabayashi, G, Takayanagi, A, Totsugawa, T, Harada, H, Obara, H, Suganuma, K, Berthiaume, F, Shimazu, M, Shimizu, N, Tanaka, N, Kitajima, M, Tompkins, RG, Toner, M & Yarmush, ML 2007, 'A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats', Journal of Surgical Research, vol. 137, no. 1, pp. 130-140. https://doi.org/10.1016/j.jss.2006.08.009
Shinoda, Masahiro ; Tilles, Arno W. ; Kobayashi, Naoya ; Wakabayashi, Go ; Takayanagi, Atsushi ; Totsugawa, Toshinori ; Harada, Hirohisa ; Obara, Hideaki ; Suganuma, Kazuhiro ; Berthiaume, François ; Shimazu, Motohide ; Shimizu, Nobuyoshi ; Tanaka, Noriaki ; Kitajima, Masaki ; Tompkins, Ronald G. ; Toner, Mehmet ; Yarmush, Martin L. / A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats. In: Journal of Surgical Research. 2007 ; Vol. 137, No. 1. pp. 130-140.
@article{0ace1b7108d14fac9d230a382878ab55,
title = "A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats",
abstract = "Background: Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods: We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results: Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion: Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF.",
keywords = "bio-artificial liver device, fulminant hepatic failure, immortalized human hepatocytes, interleukin-1 receptor antagonist, primary rat hepatocytes",
author = "Masahiro Shinoda and Tilles, {Arno W.} and Naoya Kobayashi and Go Wakabayashi and Atsushi Takayanagi and Toshinori Totsugawa and Hirohisa Harada and Hideaki Obara and Kazuhiro Suganuma and Fran{\cc}ois Berthiaume and Motohide Shimazu and Nobuyoshi Shimizu and Noriaki Tanaka and Masaki Kitajima and Tompkins, {Ronald G.} and Mehmet Toner and Yarmush, {Martin L.}",
year = "2007",
month = "1",
doi = "10.1016/j.jss.2006.08.009",
language = "English",
volume = "137",
pages = "130--140",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats

AU - Shinoda, Masahiro

AU - Tilles, Arno W.

AU - Kobayashi, Naoya

AU - Wakabayashi, Go

AU - Takayanagi, Atsushi

AU - Totsugawa, Toshinori

AU - Harada, Hirohisa

AU - Obara, Hideaki

AU - Suganuma, Kazuhiro

AU - Berthiaume, François

AU - Shimazu, Motohide

AU - Shimizu, Nobuyoshi

AU - Tanaka, Noriaki

AU - Kitajima, Masaki

AU - Tompkins, Ronald G.

AU - Toner, Mehmet

AU - Yarmush, Martin L.

PY - 2007/1

Y1 - 2007/1

N2 - Background: Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods: We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results: Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion: Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF.

AB - Background: Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods: We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results: Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion: Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF.

KW - bio-artificial liver device

KW - fulminant hepatic failure

KW - immortalized human hepatocytes

KW - interleukin-1 receptor antagonist

KW - primary rat hepatocytes

UR - http://www.scopus.com/inward/record.url?scp=33845392064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845392064&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2006.08.009

DO - 10.1016/j.jss.2006.08.009

M3 - Article

VL - 137

SP - 130

EP - 140

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -